Merck & Co and Dewpoint seek cure in HIV

14 July 2020
dewpoint_large

Privately-held Dewpoint Therapeutics has announced an exclusive collaboration with Merck & Co (NYSE: MRK), the US pharma giant known as MSD outside the USA and Canada.

The companies will apply Dewpoint’s proprietary platform for condensate-based drug discovery to the development of a new mechanism for the treatment of HIV.

"An HIV drug candidate with a unique mechanism may cure rather than suppress the infection"Biomolecular condensates are droplet-like structures that form dynamically within cells when diverse communities of proteins, RNAs, and other biomolecules come together through a process called phase separation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology